Piclidenoson is under clinical development by Can-Fite BioPharma and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase III drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Piclidenoson’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Piclidenoson overview
Piclidenoson (CF-101) is under development for the treatment of moderate-to-severe plaque psoriasis. The therapeutic candidate is formulated as tablet and administered through oral route and through topical route. The drug candidate comprises of IB-MECA as the active ingredient. It acts by targeting A3 adenosine receptor (A3AR). It was also under development for the treatment of noninfectious intermediate or posterior uveitis osteoarthritis, dry eye, Crohn's disease, rheumatoid arthritis, Sjogren's syndrome, ocular hypertension, open-angle glaucoma, neuropathic pain, chemotherapy-induced peripheral neuropathy, coronavirus disease 2019 (COVID-19), and metastatic colorectal cancer.
See Also:
Can-Fite BioPharma overview
Can-Fite BioPharma (Can-Fite), is a clinical stage drug development company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheumatoid arthritis and psoriasis; CF102, for hepatocellular carcinoma; and CF602, for erectile dysfunction. Can-Fite develops its products by harnessing its technology platform which is based on the Gi protein associates A3 adenosine receptor (A3AR). The company works in collaboration with pharmaceutical and biotechnology companies to develop its product portfolio. It has operations in Israel and the US. Can-Fite is headquartered in Petah Tikva, Israel.
For a complete picture of Piclidenoson’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
